Glioblastoma is a recurrent malignant brain tumor. The life expectancy of such patients remains extremely low. Most patients have a tumor recurrence during the first year after its diagnosis, despite ongoing complex therapy. Glioblastoma is a highly vascularized tumor, and the efficacy of regorafenib as an inhibitor of multiple protein kinases, including kinases involved in tumor angiogenesis, was studied in the phase II randomized, multicentre, open-label trial REGOMA. The article presents a brief review of the study and a clinical case of prescribing regorafenib in combination with bevacizumab in the 3rd line of therapy for a patient with glioblastoma without MGMT gene methylation and IDH1 and IDH2 mutations in the tumor. The time to progression was 5 months.

Keywords: regorafenib, glioblastoma recurrence, glioblastoma, targeted therapy